Resource Type

Journal Article 1

Year

2022 1

Keywords

Btk inhibitor 1

abivertinib 1

megakaryocyte 1

megakaryopoiesis 1

platelet 1

thrombopoiesis 1

open ︾

Search scope:

排序： Display mode:

Abivertinib inhibits megakaryocyte differentiation and platelet biogenesis

Frontiers of Medicine 2022, Volume 16, Issue 3,   Pages 416-428 doi: 10.1007/s11684-021-0838-5

Abstract: Abivertinib, a third-generation tyrosine kinase inhibitor, is originally designed to target epidermalPrevious studies have shown that abivertinib has promising antitumor activity and a well-tolerated safetyHowever, abivertinib also exhibited high inhibitory activity against Bruton’s tyrosine kinase and Janusand observed megakaryopoiesis to determine the biological effect of abivertinib on MK differentiationThese results suggested that megakaryopoiesis was inhibited by abivertinib.

Keywords： abivertinib     Btk inhibitor     platelet     megakaryocyte     megakaryopoiesis     thrombopoiesis    

HTML PDF Collect

Title Author Date Type Operation

Abivertinib inhibits megakaryocyte differentiation and platelet biogenesis

Journal Article